b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29440309</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>05</Month>\n            <Day>28</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>05</Month>\n            <Day>28</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1521-0103</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>365</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>04</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The Journal of pharmacology and experimental therapeutics</Title>\n                <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in <i>N</i>-Methyl-d-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>179-188</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.117.245506</ELocationID>\n            <Abstract>\n                <AbstractText>The pathophysiology of schizophrenia has been associated with glutamatergic dysfunction. Modulation of the glutamatergic signaling pathway, including <i>N</i>-methyl-d-aspartate (NMDA) receptors, can provide a new therapeutic target for schizophrenia. Phosphodiesterase 2A (PDE2A) is highly expressed in the forebrain, and is a dual substrate enzyme that hydrolyzes both cAMP and cGMP, which play pivotal roles as intracellular second messengers downstream of NMDA receptors. Here we characterize the in vivo pharmacological profile of a selective and brain-penetrant PDE2A inhibitor, (<i>N</i>-{(1<i>S</i>)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-<i>b</i>]pyrazine-4(1<i>H</i>)-carboxamide) (TAK-915) as a novel treatment of schizophrenia. Oral administration of TAK-915 at 3 and 10 mg/kg significantly increased cGMP levels in the frontal cortex, hippocampus, and striatum of rats. TAK-915 at 10 mg/kg significantly upregulated the phosphorylation of <i>\xce\xb1</i>-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor subunit GluR1 in the rat hippocampus. TAK-915 at 3 and 10 mg/kg significantly attenuated episodic memory deficits induced by the NMDA receptor antagonist (+)-MK-801 hydrogen maleate (MK-801) in the rat passive avoidance test. TAK-915 at 10 mg/kg significantly attenuated working memory deficits induced by MK-801 in the rat radial arm maze test. Additionally, TAK-915 at 10 mg/kg prevented subchronic phencyclidine-induced social withdrawal in social interaction in rats. In contrast, TAK-915 did not produce antipsychotic-like activity; TAK-915 had little effect on MK-801- or methamphetamine-induced hyperlocomotion in rats. These results suggest that TAK-915 has a potential to ameliorate cognitive impairments and social withdrawal in schizophrenia.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2018 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Nakashima</LastName>\n                    <ForeName>Masato</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Imada</LastName>\n                    <ForeName>Haruka</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shiraishi</LastName>\n                    <ForeName>Eri</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ito</LastName>\n                    <ForeName>Yuki</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Suzuki</LastName>\n                    <ForeName>Noriko</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Miyamoto</LastName>\n                    <ForeName>Maki</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Taniguchi</LastName>\n                    <ForeName>Takahiko</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Iwashita</LastName>\n                    <ForeName>Hiroki</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroscience Drug Discovery Unit (M.N., H.Im., E.S., Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan hiroki.iwashita@takeda.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>02</Month>\n                <Day>13</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Pharmacol Exp Ther</MedlineTA>\n            <NlmUniqueID>0376362</NlmUniqueID>\n            <ISSNLinking>0022-3565</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C000624701">TAK-915</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>E0399OZS9N</RegistryNumber>\n                <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.1.4.17</RegistryNumber>\n                <NameOfSubstance UI="D054678">Cyclic Nucleotide Phosphodiesterases, Type 2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>H2D2X058MU</RegistryNumber>\n                <NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>TFZ3H25BS1</RegistryNumber>\n                <NameOfSubstance UI="C097222">glutamate receptor ionotropic, AMPA 1</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054678" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 2</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>10</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>02</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>5</Month>\n                <Day>29</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29440309</ArticleId>\n            <ArticleId IdType="pii">jpet.117.245506</ArticleId>\n            <ArticleId IdType="doi">10.1124/jpet.117.245506</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'